Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant human atrial natriuretic peptide in acute or acutely decompensated heart failure
ChiCTR-IPR-14005719Phase 3Completed
- Sponsor
- State Key Laboratory of Cardiovascular Disease
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of carperitide in heart failure (HF), Acute Heart Failure (AHF) and chronic heart failure (CHF) (2 arms), sponsored by State Key Laboratory of Cardiovascular Disease. Primary endpoint: pulmonary capillary wedge pressure. Started Mar 2009; status: completed.
02
Drugs
carperitide
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)chronic heart failure (CHF)
Beyond the preview
Go deeper on ChiCTR-IPR-14005719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005719.